Department: DRUG CHALLENGE
Can you identify these dermatologic drugs and educate your patients about using them correctly? To find out, match each brand name in Section I with its generic name in Section II.
_____ 1. Enstilar (Leo Pharma)
_____ 2. Taltz (Eli Lilly)
_____ 3. Ameluz (Biofrontera)
a. aminolevulinic acid. This topical photosensitizing gel is indicated for lesion-directed and field-directed treatment of mild-to-moderate actinic keratosis of the scalp and face. It's used in conjunction with photodynamic therapy with a narrow-band red light illumination source. It can be applied by medical professionals only and may not be self-administered by patients. After application, patients should avoid sunlight exposure, bright indoor lights, and tanning beds for 48 hours.
b. ixekizumab. Categorized as a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody, this drug is an interleukin-17A receptor antagonist indicated for adults with moderate-to-severe plaque psoriasis. It's administered as a subcutaneous injection at a one-time dose of 160 mg, followed by 80 mg every 2 weeks until week 12, then every 4 weeks thereafter. This drug may increase the risk of infections, including (but not limited to) upper respiratory tract infection, oral candidiasis, conjunctivitis and tinea infections. Use with caution in patients with a chronic infection or a history of recurrent infections.
c. calcipotriene and betamethasone. This drug combines a vitamin D analog and a topical corticosteroid. Available as a foam spray, it's indicated to treat plaque psoriasis in patients age 18 and older. It can be applied to affected areas of skin once daily for up to 4 weeks. Tell patients to shake the container before each use and to avoid applying the foam to the eyes or face, axillae, or groin. The propellants are flammable, so instruct patients to avoid fire, flame, and smoking during and immediately following application.
Resources available upon request.
ANSWERS: 1c, 2b, 3a